GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alaunos Therapeutics Inc (NAS:TCRT) » Definitions » 12-1 Month Momentum %

TCRT (Alaunos Therapeutics) 12-1 Month Momentum % : -90.64% (As of Apr. 10, 2025)


View and export this data going back to 2005. Start your Free Trial

What is Alaunos Therapeutics 12-1 Month Momentum %?

12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2025-04-10), Alaunos Therapeutics's 12-1 Month Momentum % is -90.64%.

The industry rank for Alaunos Therapeutics's 12-1 Month Momentum % or its related term are showing as below:

TCRT's 12-1 Month Momentum % is ranked worse than
95.79% of 1448 companies
in the Biotechnology industry
Industry Median: -23.49 vs TCRT: -90.64

Competitive Comparison of Alaunos Therapeutics's 12-1 Month Momentum %

For the Biotechnology subindustry, Alaunos Therapeutics's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alaunos Therapeutics's 12-1 Month Momentum % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alaunos Therapeutics's 12-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Alaunos Therapeutics's 12-1 Month Momentum % falls into.


;
;

Alaunos Therapeutics  (NAS:TCRT) 12-1 Month Momentum % Calculation

12-1 Month Momentum % is calculated as following:

12-1 Month Momentum %=( Price 1-month ago / Price 12-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Alaunos Therapeutics  (NAS:TCRT) 12-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.


Alaunos Therapeutics 12-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of Alaunos Therapeutics's 12-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.


Alaunos Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
2617 Bissonnet Street, Suite 225, Houston, TX, USA, 77005
Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens arising from genomic mutations.
Executives
Boyle Kevin S. Sr. director, officer: Chief Executive Officer C/O ZIOPHARM ONCOLOGY, INC., ONE FIRST AVENUE, PARRIS BLDG 34, BOSTON MA 02129
Robert Hofmeister director C/O TCR2 THERAPEUTICS INC., 100 BINNEY STREET, CAMBRIDGE MA 02142
Jaime Vieser director ONE FIRST AVENUE, PARRIS BUILDING 34, NAVY YARD PLAZA, BOSTON MA 02129
Robert W Postma director 141 MECOX ROAD, WATER MILL NY 11976
Michael Wong officer: VP, Finance C/O ZIOPHARM ONCOLOGY, INC., ONE FIRST AVENUE, PARRIS BUILDING #34, BOSTON MA 02129
Abhishek K Srivastava officer: See Remarks C/O ALAUNOS THERAPEUTICS, INC., 8030 EL RIO ST., HOUSTON TX 77054
Holger Weis director C/O ZIOPHARM ONCOLOGY, INC., ONE FIRST AVENUE, PARRIS BLDG 34, BOSTON MA 02129
Christopher Bowden director 38 SIDNEY STREET, 2ND FLOOR, CAMBRIDGE MA 02139
Mary Thistle director C/O VIACELL, INC., 245 FIRST STREET, CAMBRIDGE MA 02142
James Huang director 9620 MEDICAL CENTER DRIVE, SUITE 300, ROCKVILLE MD 20850
Drew Deniger officer: VP, Research & Development C/O ALAUNOS THERAPEUTICS, INC., 8030 EL RIO ST., HOUSTON TX 77054
Groot Eleanor De officer: EVP, Operations C/O ZIOPHARM ONCOLOGY, INC., ONE FIRST AVENUE, PARRIS BLDG 34, BOSTON MA 02129
Melinda Lackey officer: Senior Vice President, Legal C/O ZIOPHARM ONCOLOGY INC., 8030 EL RIO ST, HOUSTON TX 77054
Heidi Hagen director AASTROM BIOSCIENCES, INC., 24 FRANK LLOYD WRIGHT DRIVE, ANN ARBOR MI 48105
Raffaele Baffa officer: Chief Medical Officer C/O ZIOPHARM ONCOLOGY, INC., ONE FIRST AVENUE, PARRIS BLDG 34, BOSTON MA 02129

Alaunos Therapeutics Headlines

From GuruFocus

Q2 2019 ZIOPHARM Oncology Inc Earnings Call Transcript

By GuruFocus Research 02-09-2024

Q2 2020 ZIOPHARM Oncology Inc Earnings Call Transcript

By GuruFocus Research 02-09-2024

Q4 2022 Alaunos Therapeutics Inc Earnings Call Transcript

By GuruFocus Research 02-09-2024

Q3 2022 Alaunos Therapeutics Inc Earnings Call Transcript

By GuruFocus Research 02-09-2024

Q4 2018 ZIOPHARM Oncology Inc Earnings Call Transcript

By GuruFocus Research 02-09-2024

Q3 2021 ZIOPHARM Oncology Inc Earnings Call Transcript

By GuruFocus Research 02-09-2024

Q4 2020 ZIOPHARM Oncology Inc Earnings Call Transcript

By GuruFocus Research 02-09-2024

Q1 2021 ZIOPHARM Oncology Inc Earnings Call Transcript

By GuruFocus Research 02-09-2024